HC Wainwright Brokers Lower Earnings Estimates for NeuroPace

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at HC Wainwright reduced their Q3 2027 earnings per share (EPS) estimates for shares of NeuroPace in a report issued on Thursday, August 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.05 per share for the quarter, down from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2027 earnings at $0.11 EPS and FY2027 earnings at $0.09 EPS.

A number of other brokerages have also commented on NPCE. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a report on Wednesday, June 24th. Mizuho began coverage on NeuroPace in a research report on Thursday, July 23rd. They set an “outperform” rating and a $22.00 target price for the company. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NeuroPace presently has an average rating of “Moderate Buy” and a consensus target price of $19.29.

NeuroPace Stock Up 1.2%

NASDAQ:NPCE opened at $14.64 on Thursday. NeuroPace has a one year low of $8.17 and a one year high of $19.60. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The company has a market cap of $502.44 million, a PE ratio of -25.68 and a beta of 1.92. The firm’s 50 day simple moving average is $15.40 and its 200 day simple moving average is $15.34.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%.The firm had revenue of $22.83 million for the quarter, compared to analyst estimates of $22.61 million.

Institutional Investors Weigh In On NeuroPace

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in NeuroPace during the 2nd quarter worth about $39,369,000. First Light Asset Management LLC boosted its position in shares of NeuroPace by 82.3% during the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after purchasing an additional 1,110,484 shares in the last quarter. Deutsche Bank AG acquired a new stake in NeuroPace during the second quarter worth approximately $14,919,000. Kotler Kevin acquired a new stake in NeuroPace during the fourth quarter worth approximately $9,750,000. Finally, Walleye Capital LLC increased its holdings in NeuroPace by 344.6% in the fourth quarter. Walleye Capital LLC now owns 228,847 shares of the company’s stock worth $3,533,000 after purchasing an additional 177,375 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.